- Home
- RPID vs HURA Comparison
RPID vs HURA Comparison
Compare RPID & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPID
- HURA
- Stock Information
- Founded
- RPID 2006
- HURA 2009
- Country
- RPID United States
- HURA United States
- Employees
- RPID N/A
- HURA N/A
- Industry
- RPID Medical Specialities
- HURA
- Sector
- RPID Health Care
- HURA
- Exchange
- RPID Nasdaq
- HURA Nasdaq
- Market Cap
- RPID 106.5M
- HURA 126.1M
- IPO Year
- RPID 2021
- HURA N/A
- Fundamental
- Price
- RPID $3.03
- HURA $2.50
- Analyst Decision
- RPID Strong Buy
- HURA Strong Buy
- Analyst Count
- RPID 2
- HURA 2
- Target Price
- RPID $8.00
- HURA $11.50
- AVG Volume (30 Days)
- RPID 64.5K
- HURA 274.3K
- Earning Date
- RPID 10-31-2025
- HURA 08-14-2025
- Dividend Yield
- RPID N/A
- HURA N/A
- EPS Growth
- RPID N/A
- HURA N/A
- EPS
- RPID N/A
- HURA N/A
- Revenue
- RPID $30,289,000.00
- HURA N/A
- Revenue This Year
- RPID $16.63
- HURA N/A
- Revenue Next Year
- RPID $21.98
- HURA N/A
- P/E Ratio
- RPID N/A
- HURA N/A
- Revenue Growth
- RPID 22.57
- HURA N/A
- 52 Week Low
- RPID $0.80
- HURA $1.80
- 52 Week High
- RPID $4.50
- HURA $8.40
- Technical
- Relative Strength Index (RSI)
- RPID 55.88
- HURA 44.51
- Support Level
- RPID $2.63
- HURA $2.28
- Resistance Level
- RPID $3.11
- HURA $2.65
- Average True Range (ATR)
- RPID 0.19
- HURA 0.17
- MACD
- RPID 0.09
- HURA -0.04
- Stochastic Oscillator
- RPID 89.63
- HURA 23.91
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.